Daré Bioscience Inc. (DARE)
Daré Bioscience Statistics
Share Statistics
Daré Bioscience has 8.7M shares outstanding. The number of shares has increased by -91.39% in one year.
| Shares Outstanding | 8.7M |
| Shares Change (YoY) | -91.39% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.11% |
| Shares Floating | 8.71M |
| Failed to Deliver (FTD) Shares | 193 |
| FTD / Avg. Volume | 0.81% |
Short Selling Information
The latest short interest is 29.39K, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 29.39K |
| Short % of Shares Out | 0.34% |
| Short % of Float | 0.34% |
| Short Ratio (days to cover) | 0.64 |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is -1.62. Daré Bioscience's PEG ratio is 0.
| PE Ratio | -0.01 |
| Forward PE | -1.62 |
| PS Ratio | 2.71 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Daré Bioscience.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of -0.22.
| Current Ratio | 0.85 |
| Quick Ratio | 0.85 |
| Debt / Equity | -0.22 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | 0.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $425.39K |
| Profits Per Employee | $-176.24M |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -49.65% in the last 52 weeks. The beta is 1.38, so Daré Bioscience's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -49.65% |
| 50-Day Moving Average | 3.05 |
| 200-Day Moving Average | 3.42 |
| Relative Strength Index (RSI) | 43.56 |
| Average Volume (20 Days) | 23.96K |
Income Statement
In the last 12 months, Daré Bioscience had revenue of 9.78M and earned -4.05B in profits. Earnings per share was -477.04.
| Revenue | 9.78M |
| Gross Profit | 9.78M |
| Operating Income | -23.45B |
| Net Income | -4.05B |
| EBITDA | -23.45B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -477.04 |
Balance Sheet
The company has 15.7B in cash and 1.3B in debt, giving a net cash position of 14.4B.
| Cash & Cash Equivalents | 15.7B |
| Total Debt | 1.3B |
| Net Cash | 14.4B |
| Retained Earnings | -175.29B |
| Total Assets | 18.06M |
| Working Capital | 1.79M |
Cash Flow
In the last 12 months, operating cash flow was 5.39B and capital expenditures -573.05M, giving a free cash flow of 4.82B.
| Operating Cash Flow | 5.39B |
| Capital Expenditures | -573.05M |
| Free Cash Flow | 4.82B |
| FCF Per Share | 567.37 |
Margins
Gross margin is 100%, with operating and profit margins of -239692.2% and -41430.9%.
| Gross Margin | 100% |
| Operating Margin | -239692.2% |
| Pretax Margin | -41430.9% |
| Profit Margin | -41430.9% |
| EBITDA Margin | -239692.2% |
| EBIT Margin | -239692.2% |
| FCF Margin | 49276.38% |
Dividends & Yields
DARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DARE is $13, which is 346.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 346.7% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 1, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Jul 1, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -16.39 |
| Piotroski F-Score | 2 |